What FDA’s record states
| Field | What FDA’s record states | Source |
|---|---|---|
| Recipient | www.buynetmeds.com | FDA letter ↗ |
| Location | Not published by FDA | n/a |
| Letter date | Jun 12, 2025 | FDA letter ↗ |
| Posted by FDA | Jul 1, 2025 | FDA index ↗ |
| Issuing office | Center for Drug Evaluation and Research (CDER) | FDA letter ↗ |
| Subject | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet | FDA letter ↗ |
| MARCS-CMS number | 706335 | FDA letter ↗ |
| GLP-1 drugs named | Semaglutide | FDA letter ↗ |
| Response letter | Not published by FDA | FDA letter ↗ |
| Closeout letter | Not published by FDA | FDA letter ↗ |
“FDA has also observed that www.buynetmeds.com introduces into interstate commerce unapproved and misbranded semaglutide drug products, including injectable versions. Injectable drug products can pose a serious risk of harm to users because they bypass many of the body’s natural defenses against toxic ingredients, toxins, or dangerous organisms that can lead to serious and life-threatening conditions such as septicemia or sepsis.”FDA warning letter to www.buynetmeds.com, Jun 12, 2025 · read the full letter on fda.gov ↗
What this is and is not.A warning letter is FDA’s statement of what it considers significant violations. It is an allegation, not a court finding, and the firm can respond. A closeout letter is posted when FDA confirms the violations were corrected.
Source
Every field above is copied from FDA’s page for this letter, read Oct 3, 2026. The letter on fda.gov ↗ · All 161 GLP-1 warning letters